NAVEEN PEMMARAJU to Neoplasms
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Neoplasms.
Connection Strength
0.745
-
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023 05 23; 7(10):2000-2003.
Score: 0.145
-
Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. Leuk Lymphoma. 2021 09; 62(9):2253-2260.
Score: 0.124
-
Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 04; 35(2):409-429.
Score: 0.123
-
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2?Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM. Curr Hematol Malig Rep. 2017 12; 12(6):598-604.
Score: 0.099
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
Score: 0.038
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
Score: 0.035
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.034
-
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021 05; 18(5):313-319.
Score: 0.031
-
Leveraging Social Media for Cardio-Oncology. Curr Treat Options Oncol. 2020 08 13; 21(10):83.
Score: 0.030
-
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2020 04; 61(4):963-966.
Score: 0.028
-
Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Curr Hematol Malig Rep. 2016 12; 11(6):449-455.
Score: 0.023
-
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
Score: 0.023
-
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
Score: 0.006
-
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
Score: 0.005